Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
Authors:
Open Access
- 22 August 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 10, 253
Abstract
Cerebrospinal fluid (CSF) biomarkers can enhance the early and accurate etiologic detection of Alzheimer’s disease (AD) even when symptoms are very mild, but are not yet widely available for clinical testing. There are a number of reasons for this, including the need for an experienced operator, the use of instruments mostly reserved for research, and low cost-effectiveness when patient samples do not completely fill each assay plate. Newer technology can overcome some of these issues through automated assays of a single patient sample on existing clinical laboratory platforms, but it is not known how these newer automated assays compare with previous research-based measurements. This is a critical issue in the clinical translation of CSF AD biomarkers because most cohort and clinicopathologic studies have been analyzed on older assays. To determine the correlation of CSF beta-amyloid 1-42 (Abeta42) measures derived from the automated chemiluminescent enzyme immunoassay (CLEIA, on Lumipulse® G1200), a bead-based Luminex immunoassay, and a plate-based enzyme-linked immunoassay (ELISA), we analyzed 30 CSF samples weekly on each platforms over three weeks. We found that, while CSF Abeta42 levels were numerically closer between CLEIA and ELISA measurements, levels differed between all three assays. CLEIA-based measures correlated linearly with the two other assays in the low and intermediate Abeta42 concentrations, while there was a linear correlation between Luminex assay and ELISA throughout all concentrations. For repeatability, the average intra-assay coefficient of variation (CV) was 2.0%. For intermediate precision, the inter-assay CV was lower in CLEIA (7.1%) than Luminex (10.7%, p = 0.009) and ELISA (10.8%, p= 0.009), primarily due to improved intermediate precision in the higher CSF Abeta42 concentrations. We conclude that the automated CLEIA generated reproducible CSF Abeta42 measures with improved intermediate precision over experienced operators using Luminex assays and ELISA, and are highly correlated with the manual Abeta42 measures.Keywords
Funding Information
- Emory University
This publication has 29 references indexed in Scilit:
- Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variabilityClinica Chimica Acta, 2015
- CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?Annals of Clinical and Translational Neurology, 2014
- Comparison of LUMIPULSE® G1200 With Kryptor and Modular E170 for the Measurement of Seven Tumor MarkersJournal of Clinical Laboratory Analysis, 2014
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer DiseaseArchives of Neurology, 2012
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseasesActa Neuropathologica, 2012
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer DiseaseArchives of General Psychiatry, 2004
- CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective StudyExperimental Neurology, 2000